Vincent Chung, MD
Hematology · Duarte, CANPI 1588771364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,880 of the $57,396 with a category attached, or 86.9%. 12 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 53.5% of the total. Reporting peaked in 2019 at $29,578 and has fallen 99.8% since, to $47 in 2025.
Across 76 payments — averaging $755.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$31K
- Bristol Myers Squibb$10K
- Coherus Oncology, Inc.$10K
- AstraZeneca$6K
- Eisai Inc.$282
- Caldera Medical, Inc$137
- plus $302 from 6 others
Across 419 payments — averaging $26,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$8.1M
- Takeda Pharmaceuticals U.S.A., Inc.$667K
- Roche Products Limited$454K
- Amgen$400K
- Genentech, Inc.$334K
- Ipsen Bioscience Inc.$318K
- plus $813K from 10 others
What the payments were for
- Consulting fees$3,1806%
- Speaking & faculty fees$49,88087%
- Travel & lodging$1,5203%
- Food & beverage$2,8165%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 32 | $30,694 |
| Bristol Myers Squibb | 11 | $10,497 |
| Coherus Oncology, Inc. | 11 | $9,842 |
| AstraZeneca | 4 | $5,641 |
| Eisai Inc. | 5 | $282 |
| Caldera Medical, Inc | 1 | $137 |
| Array Biopharma Inc | 4 | $90 |
| Astellas Pharma US Inc | 4 | $78 |
| F. Hoffmann-la Roche AG | 1 | $61 |
| Gilead | 1 | $27 |
| Novartis | 1 | $25 |
| Bayer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,396 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $17,768 |
| Pantoprazole Sodium | 13 | $200 |
| Ondansetron Hcl | 24 | $157 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $141 |
| Prochlorperazine Maleate | 14 | $140 |
Paid to pharmacies, not to this prescriber.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.